Azitra (AZTR) Other Accumulated Expenses (2022 - 2023)
Azitra's (AZTR) quarterly Other Accumulated Expenses came in at $23647.0 in Q4 2023, down 24.17% YoY from $31186.0 in Q4 2022, and up 649.51% on a QoQ basis from $3155.0 in Q3 2023.
Azitra (AZTR) Other Accumulated Expenses (2022 - 2023) Analysis & Trends
Azitra (AZTR) has 2 years of Other Accumulated Expenses data on file, last reported at $23647.0 in Q4 2023.
- Quarterly Other Accumulated Expenses fell 24.17% year-over-year to $23647.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $23647.0 (down 24.17% YoY) and the FY2023 annual result came in at $23647.0, down 24.17% from the prior year.
- Other Accumulated Expenses rose to $23647.0 in Q4 2023, from $3155.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $31186.0 in Q4 2022 to a low of $3155.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 23,647.00 |
| Sep 30, 2023 | 3,155.00 |
| Jun 30, 2023 | 4,258.00 |
| Dec 31, 2022 | 31,186.00 |